A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 714
Last updated 2025-09-09
Summary
The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
Conditions
Interventions
- BIOLOGICAL
-
Specified dose on specified day
- BIOLOGICAL
-
Specified dose on specified days
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-11
- Primary Completion
- 2021-01-25
- Completion
- 2030-12-15
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Canada
- Chile
- Colombia
- Denmark
- Finland
- France
- Germany
- Greece
- Israel
- Italy
- Mexico
- New Zealand
- Norway
- Poland
- Romania
- Russia
- Spain
- Sweden
- United Kingdom
Study Locations
More Related Trials
-
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
NCT03978611 ·Status: TERMINATED ·Phase: PHASE1
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
NCT04099251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
NCT03743766 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
NCT05002569 ·Status: TERMINATED ·Phase: PHASE3
-
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
NCT03329846 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT05704647 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
NCT01927419 ·Status: COMPLETED ·Phase: PHASE2
-
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
NCT03448497 ·Status: COMPLETED
-
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France
NCT04550247 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
NCT02388906 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
NCT03504696 ·Status: COMPLETED
-
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
NCT04495010 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
NCT01844505 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT06101134 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
NCT03068455 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
NCT03732560 ·Status: COMPLETED
-
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
NCT02599402 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
NCT03771859 ·Status: ACTIVE_NOT_RECRUITING
-
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
NCT01621490 ·Status: COMPLETED ·Phase: PHASE1
-
Expanded Access Program With Nivolumab to Treat Melanoma
NCT02142218 ·Status: NO_LONGER_AVAILABLE
-
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
NCT02990611 ·Status: COMPLETED
-
Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
NCT03374839 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2